{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:22:08Z","timestamp":1787962928647,"version":"build-2784847793"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The published report of the MARS2 trial suggested that the addition of extended pleurectomy\/decortication to chemotherapy for pleural mesothelioma was harmful. Thus, the report goes on, all disease should be considered as unresectable and no further mesothelioma surgery for survival benefit should be considered. This statement has changed clinical practice in the UK; however, the design of the MARS2 trial has several limitations which should prevent its conclusions being over interpreted. These limitations include the following: the inclusion of too many patients who would fall outside contemporary selection criteria including age, co-morbidity and histology; the unnecessary resection of too much tissue, particularly the diaphragm, and operating on patients too late in the disease process due to less than rigorous staging. Methods: We retrospectively analysed the selection and outcome of data of 79 of the 158 (50%) patients who underwent surgery in the surgical arm of the MARS2 study who were operated by the authors in four of the five trial surgical centres. We revised the clinical staging of these patients by applying the criteria in the forthcoming 9th TNM edition including the measurement of pleural thickness. Results: Based on reported guidelines, the selection for surgery was reset as stage I or II epithelioid PM. We found that 52 (66%) of these patients (group A) would not have been considered for surgery using contemporary selection criteria for the following reasons: non-epithelioid PM in 5; cT\/4 in 35; cT2N1 in 10 and 2 cT2N0 (pN1), which would have been detected on preoperative mediastinal biopsy. Of the 27 (34%) trial patients fulfilling current criteria (group B), 12 were cT1N0, 1 was cT1N1, 6 were cT1N0pN1 and 8 were cT2N0, all with epithelioid PM. The median survival of group B was 32 (1\u201372) months, which was significantly higher than in group A: 8.5 (1\u201355) months, p &lt; 0.0005 (Mann\u2013Whitney). Conclusions: As contemporary selection criteria were not applied in MARS2, its conclusions cannot be universally applied to all those with PM. Together with the favourable postoperative survival in this selected group, we suggest that there is still scope for a further trial of surgery in early-stage epithelioid mesothelioma.<\/jats:p>","DOI":"10.3390\/cancers17050724","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:53:06Z","timestamp":1740124386000},"page":"724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Why the MARS2 Trial Does Not Mean the End of All Mesothelioma Surgery"],"prefix":"10.3390","volume":"17","author":[{"given":"David","family":"Waller","sequence":"first","affiliation":[{"name":"St Bartholomew\u2019s Hospital, London EC1A 7BE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Bilancia","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital, Glasgow G81 4DY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-0578","authenticated-orcid":false,"given":"Luigi","family":"Ventura","sequence":"additional","affiliation":[{"name":"Northern General Hospital, Sheffield S5 7AU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tenconi","sequence":"additional","affiliation":[{"name":"Northern General Hospital, Sheffield S5 7AU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Socci","sequence":"additional","affiliation":[{"name":"Northern General Hospital, Sheffield S5 7AU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bille","sequence":"additional","affiliation":[{"name":"Guy\u2019s Hospital, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"MARS 2 Investigators. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): A phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lim, E., Opitz, I., Woodard, G., Bueno, R., de Perrot, M., Flores, R., Gill, R., Jablons, D., and Pass, H. (2025). A Perspective on the MARS2 Trial. J. Thorac. Oncol.","DOI":"10.1016\/j.jtho.2024.12.014"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ripley, R.T., Adusumilli, P.S., Bograd, A.J., B\u00f6l\u00fckbas, S., Bueno, R., Cameron, R.B., de Perrot, M., Flores, R.M., Groth, S.G., and Lang-Lazdunski, L. (2024). Going to MARS may shorten our patient\u2019s survival. J. Thorac. Cardiovasc. Surg.","DOI":"10.1016\/j.jtcvs.2024.12.006"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jtho.2024.05.002","article-title":"Members of the Staging and Prognostic Factors Committee of the Advisory Boards and Participating Institutions. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma","volume":"19","author":"Nowak","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kindler, H.L., Ismaila, N., Bazhenova, L., Chu, Q., Churpek, J.E., Dagogo-Jack, I., Bryan, D.S., Drazer, M.W., Forde, P., and Husain, A.N. (2025). Treatment of Pleural Mesothelioma: ASCO Guideline Update. J. Clin. Oncol., JCO-24-02425.","DOI":"10.1200\/JCO-24-02425"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J. Surg. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jtcvs.2019.08.027","article-title":"Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis","volume":"159","author":"Lococo","year":"2020","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01243894-200602000-00014","article-title":"Macroscopic complete resection: The goal of primary surgery in multimodality therapy for pleural mesothelioma","volume":"1","author":"Sugarbaker","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.semtcvs.2013.07.002","article-title":"The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma","volume":"25","author":"Friedberg","year":"2013","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1245\/s10434-024-15984-5","article-title":"Peritoneal Dissemination in Patients with Recurrence After Post-pleurectomy\/decortication for Pleural Mesothelioma","volume":"31","author":"Nakamura","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/JTO.0b013e31824de2dc","article-title":"Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma","volume":"7","author":"Eberlein","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/ACO.0000000000000285","article-title":"Post-thoracotomy dysrhythmia","volume":"29","author":"Haverkamp","year":"2016","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1010-7940(02)00273-7","article-title":"The management of malignant pleural mesothelioma; single centre experience in 10 years","volume":"22","author":"Aziz","year":"2002","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/07853899509031953","article-title":"The genetic basis of resistance to cancer chemotherapy","volume":"27","author":"Woodhouse","year":"1995","journal-title":"Ann. Med."},{"key":"ref_17","first-page":"ivad145","article-title":"Perioperative discordance in mesothelioma cell type after pleurectomy\/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?","volume":"37","author":"Ventura","year":"2023","journal-title":"Interdiscip. CardioVasc. Thorac. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ramundo, V., Zanirato, G., and Aldieri, E. (2021). The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212216"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2302114","DOI":"10.1183\/13993003.02114-2023","article-title":"A randomised phase II study of extended pleurectomy\/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205","volume":"63","author":"Raskin","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jtho.2019.04.029","article-title":"A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, from the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce","volume":"14","author":"Friedberg","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in Malignant Pleural Mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lang-Lazdunski, L. (2025). Cytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?. Eur. J. Surg. Oncol., 109628.","DOI":"10.1016\/j.ejso.2025.109628"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma","volume":"19","author":"McNamee","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the Real-World Results from Australia, Immunotherapy Is Not a Good Option for Patients with Mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtho.2021.08.004","article-title":"Chemotherapy with or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma","volume":"17","author":"Fennell","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_29","first-page":"CD010529","article-title":"Interventions for the management of malignant pleural effusions: A network meta-analysis","volume":"4","author":"Dipper","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","first-page":"OA1560","article-title":"The Scottish Mesothelioma Network: Impact of a national MDT on overall survival in pleural mesothelioma","volume":"62","author":"Tate","year":"2023","journal-title":"Eur. Respir. J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:15Z","timestamp":1760027955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050724"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050724","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}